Evidence map›Paper›PMID 36903299›Full record

ArticleMolecules (Basel, Switzerland)2023

Induction of Drug-Resistance and Production of a Culture Medium Able to Induce Drug-Resistance in Vinblastine Untreated Murine Myeloma Cells.

Valentina Laghezza Masci, Davide Stefanoni, Angelo D'Alessandro, Marta Zambelli, Lorenzo Modesti, Daniele Pollini, Elisa Ovidi, Antonio Tiezzi

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Valentina Laghezza MasciLaboratory of Plant Cytology and Biotechnology of Natural Compounds, Department for the Innovation in Biological, Agri-Food and Forestal Systems, University of Tuscia, Largo dell'Università, snc, 01100 Viterbo, Italy.ORCID 0000-0002-7680-7404
Davide StefanoniDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Angelo D'AlessandroDepartment of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-2258-6490
Marta ZambelliLaboratory of Plant Cytology and Biotechnology of Natural Compounds, Department for the Innovation in Biological, Agri-Food and Forestal Systems, University of Tuscia, Largo dell'Università, snc, 01100 Viterbo, Italy.
Lorenzo ModestiLaboratory of Plant Cytology and Biotechnology of Natural Compounds, Department for the Innovation in Biological, Agri-Food and Forestal Systems, University of Tuscia, Largo dell'Università, snc, 01100 Viterbo, Italy.ORCID 0000-0001-8206-6625
Daniele PolliniLaboratory of Plant Cytology and Biotechnology of Natural Compounds, Department for the Innovation in Biological, Agri-Food and Forestal Systems, University of Tuscia, Largo dell'Università, snc, 01100 Viterbo, Italy.ORCID 0000-0001-7782-7960
Elisa OvidiLaboratory of Plant Cytology and Biotechnology of Natural Compounds, Department for the Innovation in Biological, Agri-Food and Forestal Systems, University of Tuscia, Largo dell'Università, snc, 01100 Viterbo, Italy.ORCID 0000-0001-8876-6331
Antonio TiezziLaboratory of Plant Cytology and Biotechnology of Natural Compounds, Department for the Innovation in Biological, Agri-Food and Forestal Systems, University of Tuscia, Largo dell'Università, snc, 01100 Viterbo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer therapies use different compounds of synthetic and natural origin. However, despite some positive results, relapses are common, as standard chemotherapy regimens are not fully capable of completely eradicating cancer stem cells. While vinblastine is a common chemotherapeutic agent in the treatment of blood cancers, the development of vinblastine resistance is often observed. Here, we performed cell biology and metabolomics studies to investigate the mechanisms of vinblastine resistance in P3X63Ag8.653 murine myeloma cells. Treatment with low doses of vinblastine in cell media led to the selection of vinblastine-resistant cells and the acquisition of such resistance in previously untreated, murine myeloma cells in culture. To determine the mechanistic basis of this observation, we performed metabolomic analyses of resistant cells and resistant drug-induced cells in a steady state, or incubation with stable isotope-labeled tracers, namely,

Indexed as

Multiple MyelomaVinblastineAnimalsDrug Resistance, NeoplasmHumansMiceNeoplasm Recurrence, LocalTumor Cells, CulturedVinblastinedrug resistancemetabolomic analysesmurine myeloma cellsvinblastinevinblastine-resistant cells

Identifiers

PMID36903299
PMCPMC10004247

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read21
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.